Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Customers with outstanding orders should contact their payment provider to dispute charges if products are not delivered
Higher-dose semaglutide demonstrating 20.7% weight loss reinforces the pharmacological ceiling for single-receptor GLP-1 RA monotherapy
Retatrutide is an investigational peptide that acts as a triple agonist at GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes (Jastreboff et al
Retatrutide weight-loss shot - triple-action for bariatric-level results without surgery
Rybelsus is typically considered for adults with type 2 diabetes who have not achieved adequate glycaemic control with lifestyle modifications and first-line oral therapies, particularly metformin
US$ 26.16
US$ 20.87
US$ 24.41
US$ 26.10
US$ 28.01
US$ 26.26
US$ 28.84
US$ 24.71
US$ 25.52
